Clinical Data Beam one-ups Wave as both show promise of genetic editing for AATD BioSpaceWhile both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets,...Rare DiseaseRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets,… Rare Disease Read full story Post navigation Previous: Parabilis follows hefty Regeneron deal with IPO pushNext: Pepaxti study supports use in wider myeloma population Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026